Maliheh Karimpour; Nasrin Moghadas Sharif; Naser Shoeibi; Negareh Yazdani; Asieh Ehsaei
Abstract
Introduction:The present study aimed to compare the anterior segment measurements between optical low-coherence reflectometry (LenStar LS900) and anterior segment optical coherence tomography (CASIA2 OCT). Methods:A total of 198 right eyes of 198 healthy participants were used for the current study, ...
Read More
Introduction:The present study aimed to compare the anterior segment measurements between optical low-coherence reflectometry (LenStar LS900) and anterior segment optical coherence tomography (CASIA2 OCT). Methods:A total of 198 right eyes of 198 healthy participants were used for the current study, according to the inclusion and exclusion criteria. Ocular biometry parameters, such as central corneal thickness (CCT), anterior chamber depth (ACD), keratometry, and anterior chamber width (ACW), were measured usingLenStar LS 900 and CASIA2 OCT. The differences and correlations were assessed between these two instruments. The agreement was calculated as the 95% limits of agreement (LoA). Results: Among 198 subjects with a mean age of 29.39±7.88 years who enrolled in the study, 106 individuals (53.5%) were women. The mean CCT values were 531.7±35.25 and 527.3±37.82 µm for LenStar and OCT, respectively (P˂0.0001). The ACD measurements showed 2.92±0.40 and 2.95±0.43 mm for LenStar and OCT, respectively (P=0.0549). The ACW mean values were 12.04±0.52 and 11.79±0.49 mm by LenStar and OCT (P˂0.0001). The 95% LoA between the two instruments were within the ranges of -20.79 to 29.43 µm, -0.50 to -0.43 mm, -0.32 to 0.82 mm, and -0.70 to 0.87 D for CCT, ACD, ACW, and astigmatism, respectively. Conclusion: LenStar and OCT showed to have interchangeable ACD measurements; however, the results of CCT, ACW, and corneal astigmatism measured by these two instruments demonstrated clinically significant differences
Zahra Ameri Golestan; Nasrin Moghadas Sharif; Nasser Shoeibi; Asieh Ehsaei; Alireza Eslampour; Maryam Kadkhoda; Javad Heravian Shandiz
Abstract
Introduction: This study aimed to investigate the effect of phacoemulsification on macular thickness and volume in diabetic patients without retinopathy using optical coherence tomography (OCT).Methods: This prospective study included 37 diabetics and 55 non-diabetic patients (n=92) with cataract who ...
Read More
Introduction: This study aimed to investigate the effect of phacoemulsification on macular thickness and volume in diabetic patients without retinopathy using optical coherence tomography (OCT).Methods: This prospective study included 37 diabetics and 55 non-diabetic patients (n=92) with cataract who were scheduled for phacoemulsification. The participants were entered into the study based on the inclusion and exclusion criteria following a complete eye examination. Macular thickness and volume were measured preoperatively as well as one month postoperatively using the OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany).Results: The present study analyzed 76 eyes of 76 patients with immature cataract. No significant differences were observed between diabetic and non-diabetic groups in terms of thickness and volume in the macular area. However, the results showed a significant increase in both groups regarding the thickness and volume after phacoemulsification. Conclusion: The results of the present study reveal that diabetes has no effects on the changes in macular thickness and volume after cataract surgery in diabetic eyes without retinopathy.
Touka Banaee; Naser Shoeibi; Hosein Ghavam Saeedi
Abstract
Introduction: Bevacizumab (Avastin) is considered as an effective strategy in the treatment of various ocular diseases. As a vascular endothelial growth factor (VEGF) inhibitor, Avastin is used to control macular edema in patients with nonproliferative diabetic retinopathy (NPDR). Therefore, in this ...
Read More
Introduction: Bevacizumab (Avastin) is considered as an effective strategy in the treatment of various ocular diseases. As a vascular endothelial growth factor (VEGF) inhibitor, Avastin is used to control macular edema in patients with nonproliferative diabetic retinopathy (NPDR). Therefore, in this study, we systematically reviewed the effects of intravitreal bevacizumab injections on nonproliferative stage of diabetic retinopathy. Methods: Scopus and PubMed were systematically searched to find articles in which the effect of Avastin (bevacizumab) had been evaluated in nonproliferative stage of diabetic retinopathy. Literature search was performed using “Avastin OR bevacizumab”, “nonproliferative stage” and “diabetic retinopathy” as keyterms in the title, keywords, and abstract.Result: All 47 articles were found in all databases, two additional records were found through reference list screening, and only 10 articles were relevant to the purpose of this study. According to the inclusion/exclusion criteria, 39 articles were excluded in several step processes of article selection. The results revealed that intravitreal injection of bevacizumab could be safely used to treat various ocular disease, particularly NPDR stage of diabetic retinopathy with macular edema.Discussion: Bevacizumab is considered as a novel and effective modality in the treatment of various ocular diseases such as retinal neovascularization, neovascular glaucoma, macular edema, and other ocular complications. Findings also suggested that bevacizumab is a suitable therapeutic approach in clinical use.Conclusion: According to the results of included documents, intravitreal injection of bevacizumab could be considered as a promising treatment modality in the clinical management of NPDR stage of diabetic retinopathy.
Naser Shoeibi; Mehran Mahdizadeh; Masoud Shafiee
Abstract
Drug delivery to the inner part of the eye is still a problem in treatment of ocular disease. Iontophoresis has been used in the field of medicine for many years. This technique consists of applying a weak electrical current to drive charged drug molecules across tissue barriers. Transcorneal iontophoresis ...
Read More
Drug delivery to the inner part of the eye is still a problem in treatment of ocular disease. Iontophoresis has been used in the field of medicine for many years. This technique consists of applying a weak electrical current to drive charged drug molecules across tissue barriers. Transcorneal iontophoresis delivers a high concentration of drug to the anterior segment of the eye (cornea, aqueous humor, ciliary body, iris, and lens), for the treatment of anterior segment diseases. There are different types of iontophoresis such as ophthalmic, transdermal, transungual, oral, buccal, and transnasal. The benefit of iontophoretic drug delivery in ophthalmology lays in its capacity to provide high drug tissue concentration safely, while minimizing the systemic drug exposure. This review summarizes basics of ocular iontophoresis and iontophoretic device, trans corneal and transscleral iontophoresis, and the applications of iontophoresis in ophthalmology.
Ali Dehghani; Habib Jafari; Naser Shoeibi
Abstract
Intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) have become more popular quickly in recent years. Bevacizumab is an anti- vascular endothelial growth factor agent (anti-VEGF) used to treat choroidal neovascularization and retinal vascular disorders. Rare long lasting ...
Read More
Intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) have become more popular quickly in recent years. Bevacizumab is an anti- vascular endothelial growth factor agent (anti-VEGF) used to treat choroidal neovascularization and retinal vascular disorders. Rare long lasting ocular adverse events are reported in the intravitreal injection of this drug that include intraocular inflammation, retinal tears, vitreous hemorrhage, endophtalmitis, and lens changes. One important concern about intravitreal injection of anti-VEGF drug is intraocular pressure (IOP) elevation. There are two kinds of IOP elevation. First one is an acute elevation of IOP (after few minutes) and the second is delayed IOP elevation (after few months). The prevalence of IOP elevation immediately after injection is significantly high and seems to have the potential risk for optic nerve fiber loss results in decreased vision but fortunately this IOP elevation seems to be transient in most of studies.